Successfully sourced $3.5M Series A funding for a preclinical IVD Device startup with products in Cardiovascular and Oncology space. Effort included drafting non-confidential "Teaser", Private Placement Memorandum, and a scientific white-paper. Along with our partners, we and our conducted investor identification, communications, and managed the process through the collection of funds.
Leveraged Asia network to identify local partners in Greater China for a client seeking entry to that market with a portfolio of branded generics across multiple TA's. Potential in-licensing partners are companies based in China as well as western firms who are seeking assets to compliment their portfolios within China.
Placing early-stage pain asset developed in APAC with western firm having synergistic offerings in area of secondary care
Seeking certain nebulizer formulations and synergistic products in respiratory space immediately available for license in greater China
Placing branded generics with a leading MNC expanding their offerings in Greater China
Assisting Beijing-based firm with rapid expansion of portfolio with solid-dose generics and branded generics across multiple TA's
Seeking strategic partners who can maximize the commercial potential of three respiratory NCE's aimed primarily at asthma and related indications
Seeking strategic partners able to maximize NCS assets in neurology space